139 related articles for article (PubMed ID: 38431184)
1. Functional evidence for two distinct mechanisms of action of progesterone and selective progesterone receptor modulator on uterine leiomyomas.
Milewska G; Ponikwicka-Tyszko D; Bernaczyk P; Lupu O; Szamatowicz M; Sztachelska M; Pilaszewicz-Puza A; Koda M; Bielawski T; Zbucka-Kretowska M; Pawelczyk A; Tomaszewski J; Li X; Huhtaniemi I; Wolczynski S; Rahman NA
Fertil Steril; 2024 Feb; ():. PubMed ID: 38431184
[TBL] [Abstract][Full Text] [Related]
2. The management of uterine leiomyomas.
Vilos GA; Allaire C; Laberge PY; Leyland N;
J Obstet Gynaecol Can; 2015 Feb; 37(2):157-178. PubMed ID: 25767949
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical localization of growth factors and their receptors in uterine leiomyomas and matched myometrium.
Dixon D; He H; Haseman JK
Environ Health Perspect; 2000 Oct; 108 Suppl 5():795-802. PubMed ID: 11035985
[TBL] [Abstract][Full Text] [Related]
4. Ulipristal acetate decreases active TGF-β3 and its canonical signaling in uterine leiomyoma via two novel mechanisms.
Lewis TD; Malik M; Britten J; Parikh T; Cox J; Catherino WH
Fertil Steril; 2019 Apr; 111(4):806-815.e1. PubMed ID: 30871768
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D as an effective treatment in human uterine leiomyomas independent of mediator complex subunit 12 mutation.
Corachán A; Trejo MG; Carbajo-García MC; Monleón J; Escrig J; Faus A; Pellicer A; Cervelló I; Ferrero H
Fertil Steril; 2021 Feb; 115(2):512-521. PubMed ID: 33036796
[TBL] [Abstract][Full Text] [Related]
6. Possible significance of degeneration and decreased expression of progesterone receptor in postmenopausal uterine leiomyoma.
Tanioka S; Asano R; Wakabayashi R; Hayashi H; Shigeta H
BMC Womens Health; 2022 Aug; 22(1):346. PubMed ID: 35974345
[TBL] [Abstract][Full Text] [Related]
7. The role of progesterone signaling in the pathogenesis of uterine leiomyoma.
Kim JJ; Sefton EC
Mol Cell Endocrinol; 2012 Jul; 358(2):223-31. PubMed ID: 21672608
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor beta and platelet-derived growth factor in human myometrium and in uterine leiomyomas at various stages of tumour growth.
Wolańska M; Bańkowski E
Eur J Obstet Gynecol Reprod Biol; 2007 Feb; 130(2):238-44. PubMed ID: 16564125
[TBL] [Abstract][Full Text] [Related]
9. The Potential of Transforming Growth Factor-beta Inhibitor and Vascular Endothelial Growth Factor Inhibitor as Therapeutic Agents for Uterine Leiomyoma.
Park JY; Chae B; Kim MR
Int J Med Sci; 2022; 19(12):1779-1786. PubMed ID: 36313223
[No Abstract] [Full Text] [Related]
10. [The molecular mechanisms and morphological manifestations of leiomyoma reduction induced by selective progesterone receptor modulators].
Demura TA; Revazova ZV; Kogan EA; Adamyan LV
Arkh Patol; 2017; 79(3):19-26. PubMed ID: 28631712
[TBL] [Abstract][Full Text] [Related]
11. The Biological Impact of Ulipristal Acetate on Cellular Networks Regulating Uterine Leiomyoma Growth.
Tinelli A; Kosmas IP; Mynbaev OA; Malvasi A; Sparic R; Vergara D
Curr Pharm Des; 2020; 26(3):310-317. PubMed ID: 31987017
[TBL] [Abstract][Full Text] [Related]
12. Epidemiological and genetic clues for molecular mechanisms involved in uterine leiomyoma development and growth.
Commandeur AE; Styer AK; Teixeira JM
Hum Reprod Update; 2015; 21(5):593-615. PubMed ID: 26141720
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of tumor necrosis factor-α on matrix metalloproteinase-2 expression in human myometrial and uterine leiomyoma smooth muscle cells.
Wang Y; Feng G; Wang J; Zhou Y; Liu Y; Shi Y; Zhu Y; Lin W; Xu Y; Li Z
Hum Reprod; 2015 Jan; 30(1):61-70. PubMed ID: 25398968
[TBL] [Abstract][Full Text] [Related]
14. Preoperative treatment of uterine leiomyomas: clinical findings and expression of transforming growth factor-beta3 and connective tissue growth factor.
De Falco M; Staibano S; D'Armiento FP; Mascolo M; Salvatore G; Busiello A; Carbone IF; Pollio F; Di Lieto A
J Soc Gynecol Investig; 2006 May; 13(4):297-303. PubMed ID: 16697947
[TBL] [Abstract][Full Text] [Related]
15. Extracellular matrix in uterine leiomyoma pathogenesis: a potential target for future therapeutics.
Islam MS; Ciavattini A; Petraglia F; Castellucci M; Ciarmela P
Hum Reprod Update; 2018 Jan; 24(1):59-85. PubMed ID: 29186429
[TBL] [Abstract][Full Text] [Related]
16. Ovarian steroids, stem cells and uterine leiomyoma: therapeutic implications.
Moravek MB; Yin P; Ono M; Coon JS; Dyson MT; Navarro A; Marsh EE; Chakravarti D; Kim JJ; Wei JJ; Bulun SE
Hum Reprod Update; 2015; 21(1):1-12. PubMed ID: 25205766
[TBL] [Abstract][Full Text] [Related]
17. Selective progesterone receptor modulator (SPRM) ulipristal acetate (UPA) and its effects on the human endometrium.
Whitaker LH; Murray AA; Matthews R; Shaw G; Williams AR; Saunders PT; Critchley HO
Hum Reprod; 2017 Mar; 32(3):531-543. PubMed ID: 28130434
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids.
Ferrero S; Vellone VG; Barra F
Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):107-116. PubMed ID: 29250979
[TBL] [Abstract][Full Text] [Related]
19. [Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women].
Szamatowicz M; Kotarski J
Ginekol Pol; 2013 Mar; 84(3):219-22. PubMed ID: 23700851
[TBL] [Abstract][Full Text] [Related]
20. The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids.
Singh SS; Belland L; Leyland N; von Riedemann S; Murji A
Am J Obstet Gynecol; 2018 Jun; 218(6):563-572.e1. PubMed ID: 29274830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
